References
- Cai Y, Wang Y, Sun J, Wang X, Xu Y, Sun C, Guo Y, Sun M, Ma K. Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report. J Int Med Res. 2020 Jun;48(6):300060520928793. DOI: 10.1177/0300060520928793
- Peng L, Zhu L, Sun Y, Stebbing J, Selvaggi G, Zhang Y, Yu Z. Targeting ALK Rearrangements in NSCLC: Current State of the Art. Front Oncol. 2022 Apr 6;12:863461. DOI: 10.3389/fonc.2022.863461
- Yin S, Chen Z, Chen D, Yan D. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. Theranostics. 2023 Mar 5;13(5):1520-1544. DOI: 10.7150/thno.80091
- NCCN Guidelines Version 3.2023 Non-Small Cell Lung Cancer, 2023
- DNA Sample Preparation Kit, Roche Diagnostics kit insert
- cobas® EGFR Mutation Test v2 insert
- SP263 (Ventana) kit insert
- OptiView DAB Amplification kit insert
- D5F3 Rabbit Monoclonal Antibody clone (Ventana) insert kit
- OptiView DAB IHC Detection Kit insert 16.
- https://www.who.int
- Hou J, Li H, Ma S, He Z, Yang S, Hao L, Zhou H, Zhang Z, Han J, Wang L, Wang Q. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomark Res. 2022 Apr 13;10(1):21. DOI: 10.1186/s40364-022-00372-6
- Melosky B, Kambartel K, Häntschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Mol Diagn Ther. 2022 Jan;26(1):7-18. DOI: 10.1007/s40291-021-00563-1
- Lahmadi M, Beddar L, Rouibah AL, Boumegoura A, Boufendi H, Temim A, et al. Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev. 2021 Apr 1;22(4):1063-1068. DOI: 10.31557/APJCP.2021.22.4.1063
- Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou D, et al. Mutation Spectrum of EGFR From 21,324 Chinese Patients with Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory. Pathol Oncol Res. 2021 Apr 7; 27:602726. DOI: 10.3389/pore.2021.602726
- Lee K, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. Cancer Res Treat. 2020 Jan;52(1):292-300. DOI: 10.4143/crt.2019.186
- Mehta A, Vasudevan S. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis. Cancer Treat Res Commun. 2021;28:100398. DOI: 10.1016/j.ctarc.2021.100398
- Kaler AK, Patel K, Patil H, Tiwarekar Y, Kulkarni B, Hastak M, et al. Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma-An Indian Perspective of 212 Patients. Int J Environ Res Public Health. 2022 Dec 31;20(1):758. DOI: 10.3390/ijerph20010758
- Kim IA, Hur JY, Kim HJ, Lee SA, Hwang JJ, Kim WS, Lee KY. Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations. Cancers (Basel). 2021 Jul 20;13(14):3632 DOI: 10.3390/cancers13143632
- Lee H, Han J, Choi YL. Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer. Diagnostics (Basel). 2021 Sep 17;11(9):1695. DOI: 10.3390/diagnostics11091695
- Gu L, Huang H, Xu Z, Niu X, Li Z, Xia L, Yu Y, Lu S. Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study. J Clin Med. 2022 Dec 28;12(1):236. DOI: 10.3390/jcm12010236
- Ko HW, Shie SS, Wang CW, Chiu CT, Wang CL, Yang TY, et al. Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation. Front Immunol. 2022 Oct 20;13:1011092. DOI: 10.3389/fimmu.2022.1011092
- Yu X, Si J, Wei J, Wang Y, Sun Y, Jin J, Zhang X, Ma T, Song Z. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study. Cancer Med. 2023 Mar;12(5):5630-5638. DOI: 10.1002/cam4.5413
- Chang JW, Huang CY, Fang YF, Chang CF, Yang CT, Kuo CS, Hsu PC, Wu CE. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. Thorac Cancer. 2023 Jan;14(1):12-23. DOI: 10.1111/1759-7714.14537
- Nakra T, Mehta A, Bal A, Nambirajan A, Mishra D, Midha D, et al. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of “Lung Cancer Management in Indian context”. Curr Probl Cancer. 2020 Jun;44(3):100561. DOI: 10.1016/j. currproblcancer.2020.100561
- Masuda K, Horinouchi H, Tanaka M, Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin Oncol. 2021 Jan;147(1):245-251. DOI: 10.1007/s00432-020-03329-0
- Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit rev oncol hematol. 2021;157:103194. DOI: 10.1016/j.critrevonc.2020.103194
- Dalurzo ML, Avilés-Salas A, Soares FA, Hou Y, Li Y, Stroganova A, et al. Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets. Onco Targets Ther. 2021 Sep 1;14:4671-4692. DOI: 10.2147/OTT.S313669